Phase III Stroke Trial

This is a randomised, controlled, phase 3 study of the safety and efficacy of intracerebral stem cells (CTX0E03 DP) in patients with disability following an ischemic stroke.

Awarded By

  • ReNeuron Group

Contributors

Amount

  • $13,544,374.00

Start/End

  • 2017 - 2020